ATE469966T1 - Verfahren zur abschätzung des risikos der expression einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkung - Google Patents

Verfahren zur abschätzung des risikos der expression einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkung

Info

Publication number
ATE469966T1
ATE469966T1 AT01270625T AT01270625T ATE469966T1 AT E469966 T1 ATE469966 T1 AT E469966T1 AT 01270625 T AT01270625 T AT 01270625T AT 01270625 T AT01270625 T AT 01270625T AT E469966 T1 ATE469966 T1 AT E469966T1
Authority
AT
Austria
Prior art keywords
administration
metabolized
adverse drug
risk
expression
Prior art date
Application number
AT01270625T
Other languages
English (en)
Inventor
Yoshinori Hasegawa
Yu-Uichi Ando
Kaoru Shimokata
Original Assignee
Inst Nagoya Ind Science Res
Sekisui Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nagoya Ind Science Res, Sekisui Medical Co Ltd filed Critical Inst Nagoya Ind Science Res
Application granted granted Critical
Publication of ATE469966T1 publication Critical patent/ATE469966T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
AT01270625T 2000-12-12 2001-12-10 Verfahren zur abschätzung des risikos der expression einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkung ATE469966T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000376756 2000-12-12
PCT/JP2001/010813 WO2002048400A1 (en) 2000-12-12 2001-12-10 Method of estimating risk of the expression of side effect caused by the administration of compound metabolized, either per se or as its metabolic intermediate, by ugt1a1 enzyme

Publications (1)

Publication Number Publication Date
ATE469966T1 true ATE469966T1 (de) 2010-06-15

Family

ID=18845576

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01270625T ATE469966T1 (de) 2000-12-12 2001-12-10 Verfahren zur abschätzung des risikos der expression einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkung

Country Status (10)

Country Link
US (4) US20040058363A1 (de)
EP (1) EP1352970B1 (de)
JP (2) JP4447835B2 (de)
KR (2) KR101651391B1 (de)
CN (1) CN100374575C (de)
AT (1) ATE469966T1 (de)
AU (1) AU2002221112A1 (de)
DE (1) DE60142309D1 (de)
ES (1) ES2346848T3 (de)
WO (1) WO2002048400A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
SK7092003A3 (en) 2000-11-09 2004-06-08 Neopharm Inc SN-38 lipid complexes and methods of use
US20030099960A1 (en) * 2001-01-26 2003-05-29 The University Of Chicago Compositions and methods for optimizing UGT2B7 substrate dosings and for predicting UGT2B7 substrate toxicity
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
WO2004027088A2 (en) * 2002-09-20 2004-04-01 UNIVERSITé LAVAL Method for determining the predisposition of patients to toxicity or lack of efficacy of a drug
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan
CA2527320A1 (en) 2003-05-30 2004-12-16 University Of Chicago Methods and compositions for predicting irinotecan toxicity
BRPI0415079A (pt) * 2003-10-06 2006-12-12 Novartis Ag biomarcadores para prognóstico de diarréia induzida por droga
US20090247475A1 (en) * 2004-03-05 2009-10-01 The Regents Of The University Of California Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
JPWO2007055261A1 (ja) * 2005-11-10 2009-04-30 財団法人新産業創造研究機構 Ｕｇｔ１ａ１遺伝子多型の検査法
EP1790343A1 (de) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
GB2432365A (en) * 2005-11-18 2007-05-23 Dxs Ltd A nucleic acid molecule for detecting polymorphisms in the UGT1A1 promoter
JP4884899B2 (ja) * 2006-09-19 2012-02-29 東洋鋼鈑株式会社 イリノテカンの副作用の発生危険度を判定する方法およびそのためのキット
CN102168141B (zh) 2006-11-30 2013-10-23 爱科来株式会社 Ugt1a1基因扩增用引物对、含有其的ugt1a1基因扩增用试剂及其用途
KR200452078Y1 (ko) * 2009-03-10 2011-01-28 주식회사 디아이디 벽지샘플북의 손잡이
JP2011250726A (ja) * 2010-06-01 2011-12-15 Toyo Kohan Co Ltd イリノテカンの副作用の発生危険度を判定する方法及びそのためのキット
CN102816858B (zh) * 2012-09-06 2014-02-19 上海源奇生物医药科技有限公司 一种检测ugt1a1基因型的引物和探针、及其试剂盒
JP6324828B2 (ja) * 2014-07-07 2018-05-16 株式会社日立製作所 薬効分析システム及び薬効分析方法
WO2016132736A1 (ja) 2015-02-17 2016-08-25 国立大学法人山口大学 イリノテカンによる副作用の発生リスクの予測を補助する方法
CN107043808A (zh) * 2017-01-19 2017-08-15 上海赛安生物医药科技有限公司 Ugt1a1基因多态性检测引物肽核酸及其试剂盒
CN109371127A (zh) * 2018-10-22 2019-02-22 江苏美因康生物科技有限公司 一种同时快速检测ugt1a1*6型与ugt1a1*28型基因多态性的试剂盒及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
EP0894145B1 (de) * 1996-03-01 2005-09-21 The University Court Of The University Of Dundee Drogen untersuchungssystem
PT1071710E (pt) * 1998-04-15 2007-01-31 Serono Genetics Inst Sa Sequência genómica da proteína activadora da 5- lipoxigenase ( flap), seus marcadores polimórficos e métodos para a detecção de asma
AU3879299A (en) * 1998-05-07 1999-11-23 Axys Pharmaceuticals, Inc. Genotyping the human udp-glucuronosyltransferase 1 (ugt1) gene
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter

Also Published As

Publication number Publication date
JPWO2002048400A1 (ja) 2004-04-15
KR101651287B1 (ko) 2016-08-26
US20090263818A1 (en) 2009-10-22
DE60142309D1 (de) 2010-07-15
US20040058363A1 (en) 2004-03-25
KR20030053064A (ko) 2003-06-27
US20070082357A1 (en) 2007-04-12
EP1352970A1 (de) 2003-10-15
JP2009195247A (ja) 2009-09-03
AU2002221112A1 (en) 2002-06-24
EP1352970A4 (de) 2004-08-25
EP1352970B1 (de) 2010-06-02
CN100374575C (zh) 2008-03-12
KR101651391B1 (ko) 2016-08-25
KR20160031023A (ko) 2016-03-21
US20110151474A1 (en) 2011-06-23
WO2002048400A1 (en) 2002-06-20
JP4447835B2 (ja) 2010-04-07
JP4616919B2 (ja) 2011-01-19
ES2346848T3 (es) 2010-10-21
CN1547613A (zh) 2004-11-17

Similar Documents

Publication Publication Date Title
ATE469966T1 (de) Verfahren zur abschätzung des risikos der expression einer durch die verabreichung einer verbindung, die entweder per se durch ugt1a1 metabolisiert wird oder deren zwischenverbindung durch das enzym metabolisiert wird, hervorgerufenen unerwünschten arzneimittelwirkung
Becker et al. Twin zygosity
Selvaraj et al. Association of vitamin D receptor genotypes with the susceptibility to pulmonary tuberculosis in female patients & resistance in female contracts
Soman et al. Activation of the c-Ki-ras oncogene in aflatoxin B1-induced hepatocellular carcinoma and adenoma in the rat: detection by denaturing gradient gel electrophoresis.
ATE186945T1 (de) Verfahren für die bestimmung eines erbguts durch vergleichung der nukleotidensequenz der mitglieder einer gen-familie und ein dafür bestimmten testsatz
DE1063294T1 (de) Dns oder gene, die an der parkinsonschen krankheit beteiligt sind
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE60045188D1 (de) T-ZELLREZEPTOR Vb-Db-Jb-SEQUENZ UND VERFAHREN FÜR IHREN NACHWEIS
BR0010739A (pt) Processo de análise da predisposição genética de um paciente a pelo menos uma doença e amplificação de uma sequência e de duas sequências
DE60041912D1 (de) Polymorphe marker des lsr-gens
WO2004001015A3 (en) Method for sequencing nucleic acids
WO2003022875A3 (en) Polymorphisms of pd-1
WO2004081191A3 (en) Molecular haplotyping of genomic dna
NZ512932A (en) A method for identifying subjects having a high or low drug metabolising phenotype associated with cytochrome CYP3A5 expression
WO2002006294A3 (en) Haplotypes of the mmp13 gene
Mani UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof
Seiwert The ins and outs of editing RNA in kinetoplastids
US20060057622A1 (en) Low cycle amplification of RNA molecules
JPWO2021072394A5 (de)
WO2003060074A3 (en) Novel metastasis suppressor gene on human chromosome 8
Yau Repeat Expansions in Movement Disorders: Disease Modification and New Horizon
WO2002026764A3 (en) Haplotypes of the ccr6 gene
WO2000047776A3 (en) Insulin-family homolog localized to chromosome 1
EP1538220A2 (de) Allelische varianten des faktor vii gens
EP1217081A3 (de) Verfahren und Reagenzien zum Nachweis eines erhöhten Risikos, eine entzündliche Krankheit zu entwickeln

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties